Study design (if review, criteria of inclusion for studies)
Systematic review
Participants
Articles about chronic rhinosinusitis in CF paritients
Interventions
Dornase alfa
Outcome measures
Sinonasal symptoms, endoscopic and radiographic findings, pulmonary function
Main results
Sixty-two articles were identified; 6 met the inclusion criteria (104 patients). Improvement measured by sinonasal symptoms, endoscopic and radiographic findings, and pulmonary function was variably reported between the studies. Sinonasal symptoms were shown to improve in all studies with use of intranasal topical dornase. Three placebo-controlled studies showed that topical dornase significantly improved sinonasal symptoms more than saline alone. The impact on pulmonary function and radiographic and endoscopy findings was variable.
Authors' conclusions
Topical intranasal dornase appears to improve sinonasal symptoms in CF patients to a greater degree than saline alone. The impact on other outcomes is less clear. Larger studies are needed to fully elucidate the true efficacy of dornase alfa in the treatment of CRS in CF patients.